A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)
A Single-Arm, Multicenter, Phase II Clinical Trial of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)
Sponsor: CStone Pharmaceuticals
A PHASE2 clinical study on Extranodal Natural Killer/T-Cell Lymphoma, this trial is completed. The trial is conducted by CStone Pharmaceuticals and has accumulated 11 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Dec 2022 — Jul 2023 [monthly]
Active Not Recruiting PHASE2
-
Mar 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 6 earlier versions
-
Mar 2021 — Mar 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Apr 2020 — Dec 2020 [monthly]
Recruiting PHASE2
-
Nov 2019 — Apr 2020 [monthly]
Recruiting PHASE2
-
Aug 2018 — Nov 2019 [monthly]
Recruiting PHASE2
First recorded
Jun 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CStone Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Changsha, China , Chengdu, China , Fuzhou, China , Guangzhou, China , Guiyang, China , Hangzhou, China , Hefei, China , Nanning, China , Shanghai, China and 4 more locations